Development of membrane type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant tumor detection

Cancer Science

Volumn 102, Issue 10, 2011, Pages 1897-1903

  Shimizu, Yoichi ^a   Temma, Takashi ^a   Sano, Kohei ^a   Ono, Masahiro ^a   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; RHODAMINE X CONJUGATED MEMBRANE TYPE 1 MATRIX METALLOPROTEINASE ANTIBODY; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE 14; MONOCLONAL ANTIBODY; TUMOR MARKER;

ANIMAL EXPERIMENT; ARTICLE; CANCER DIAGNOSIS; CELL STRAIN MCF 7; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; ENZYME SPECIFICITY; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; ENZYMOLOGY; GLIOMA; IMMUNOLOGY; NEOPLASM; NUDE MOUSE; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORESCENT DYES; GLIOMA; HUMANS; MATRIX METALLOPROTEINASE 14; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL;

EID: 84856269467     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02020.x     Document Type: Article

References (42)

1. Gindy ME, Prud'homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv 2009; 6: 865-78.
2. Alford R, Ogawa M, Choyke PL, Kobayashi H. Molecular probes for the in vivo imaging of cancer. Mol Biosyst 2009; 5: 1279-91.
3. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-74.
4. Lafleur MA, Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 2003; 5: 1-39.
5. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2: 657-72.
6. Kuge Y, Takai N, Ishino S, Temma T, Shiomi M, Saji H. Distribution profiles of membrane type-1 matrix metalloproteinase (MT1-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability analysis. Biol Pharm Bull 2007; 30: 1634-40.
7. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-33.
8. Mori H, Tomari T, Koshikawa N et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J 2002; 21: 3949-59.
9. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999; 189: 161-8.
10. Knauper V, Bailey L, Worley JR, Soloway P, Patterson ML, Murphy G. Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Lett 2002; 532: 127-30.
11. Hama Y, Urano Y, Koyama Y et al. A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a selfquenched avidin-rhodamine conjugate. Cancer Res 2007; 67: 2791-9.
12. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001; 7: 743-8.
13. Kamiya M, Kobayashi H, Hama Y et al. An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc 2007; 129: 3918-29.
14. Ogawa M, Kosaka N, Longmire MR, Urano Y, Choyke PL, Kobayashi H. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol Pharm 2009; 6: 386-95.
15. Urano Y, Asanuma D, Hama Y et al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 2009; 15: 104-9.
16. Mahmood U, Tung CH, Bogdanov A Jr, Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 1999; 213: 866-70.
17. Osenkowski P, Toth M, Fridman R. Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP). J Cell Physiol 2004; 200: 2-10.
18. Aita K, Temma T, Shimizu Y, Kuge Y, Seki K, Saji H. Synthesis of a new NIR fluorescent Nd complex labeling agent. J Fluoresc 2010; 20: 225-34.
19. Arano Y, Wakisaka K, Ohmono Y et al. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications. Bioconjug Chem 1996; 7: 628-37.
20. Lafleur MA, Mercuri FA, Ruangpanit N, Seiki M, Sato H, Thompson EW. Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain. J Biol Chem 2006; 281: 6826-40.
21. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem Biol 2009; 4: 535-46.
22. Nakada M, Okada Y, Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front Biosci 2003; 8: e261-9.
23. Yu M, Bowden ET, Sitlani J et al. Tyrosine phosphorylation mediates ConAinduced membrane type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in MDA-MB-231 human breast carcinoma cells. Cancer Res 1997; 57: 5028-32.
24. Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003; 22: 8716-22.
25. Belien AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol 1999; 144: 373-84.
26. Temma T, Sano K, Kuge Y et al. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biol Pharm Bull 2009; 32: 1272-7.
27. Wang X, Ma D, Keski-Oja J, Pei D. Co-recycling of MT1-MMP and MT3- MMP through the trans-Golgi network. Identification of DKV582 as a recycling signal. J Biol Chem 2004; 279: 9331-6.
28. Uekita T, Itoh Y, Yana I, Ohno H, Seiki M. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 2001; 155: 1345-56.29
29. R Murphy G, Roghi C. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci 2003; 116: 3905-16.
30. Gálvez BG, Matías-Roman S, Yáñez-Mo M, Vicente-Manzanares M, Sánchez-Madrid F, Arroyo AG. Caveolae are a novel pathway for membranetype 1 matrix metalloproteinase traffic in human endothelial cells. Mol Biol Cell 2004; 15: 678-87.
31. Weissleder R. A clearer vision for in vivo imaging. Nat Biotechnol 2001; 19: 316-7.
32. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
33. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992; 3: 351-62.
34. Watkins GA, Jones EF, Scott Shell M et al. Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem 2009; 17: 653-9.
35. Kondo M, Asai T, Katanasaka Y et al. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer 2004; 108: 301-6.
36. Packard BZ, Artym VV, Komoriya A, Yamada KM. Direct visualization of protease activity on cells migrating in three-dimensions. Matrix Biol 2009; 28: 3-10.
37. Zhao T, Harada H, Teramura Y et al. A novel strategy to tag matrix metalloproteinases-positive cells for in vivo imaging of invasive and metastatic activity of tumor cells. J Control Release 2010; 144: 109-14.
38. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
39. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 2003; 7: 626-34.
40. Sharma R, Wendt JA, Rasmussen JC, Adams KE, Marshall MV, Sevick-Muraca EM. New horizons for imaging lymphatic function. Ann N Y Acad Sci 2008; 1131: 13-36.
41. Kitai T, Inomoto T, Miwa M, Shikayama T. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer 2005; 12: 211-5.
42. Kikuchi M, Hosokawa K. Near-infrared fluorescence venography: a navigation system for varicose surgery. Dermatol Surg 2009; 35: 1495-8.